ArticleJournal of applied toxicology : JAT2026
Protective Effect of L-Arginine and Filgrastim Against Valproic Acid-Induced Histopathological Changes on the Gastric and Lingual Mucosa.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproic acid (VPA) is a commonly used anticonvulsant prescribed for various neurological disorders. Adverse effects may arise from chronic use and high dosages. This study aims to evaluate the protective effects of L-arginine and Filgrastim against the harmful impact of VPA on gastric and lingual mucosa. Forty male albino rats were divided into four groups (10 for each). The control group received saline, while the VPA group administered VPA (500 mg/kg) orally for 14 days. The VPA + L-arginine and VPA + Filgrastim groups received L-arginine (300 mg/kg) and Filgrastim (40 μg/kg), respectively, starting 3 days prior to VPA administration and continued concurrently with VPA for 14 days. Results revealed that VPA caused a decrease in gastric and lingual malondialdehyde (MDA) and superoxide dismutase (SOD) levels, tissue damage, and ulceration in the gastric mucosa. Lingual papillae appeared atrophied. A significant reduction in gastric mucosal thickness, parietal cell number, and fungiform papillae height was found, while the fungiform papillae width was significantly increased. Increased caspase-3 reaction in the parietal and chief cells of the gastric mucosa, as well as in the filiform and fungiform papillae of the tongue, was observed. The VPA + L-arginine and VPA + Filgrastim groups showed improvement in gastric and tongue biochemical and histological abnormalities, with a marked decrease in the caspase-3 reaction in gastric tissue. In the VPA + Filgrastim group, only the tongue tissue showed decreased caspase-3 reaction. It can be concluded that L-arginine and Filgrastim demonstrated effective protection of gastric and lingual mucosa against VPA-induced damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.